Skip to end of metadata
-
Created by Former user, last modified by Former user on Jul 26, 2021
Go to start of metadata
You are viewing an old version of this page. View the current version.
Compare with Current
View Page History
« Previous
Version 27
Next »
Project Scope This Project team will create a White Paper with recommendations for Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices. |
|
---|
Survey has been completed and went out to a sample for testing. Hoping to finalise the survey and send to a broad audience in Q3. |
Objectives & Deliverables | Timelines |
---|
White Paper with recommended definition(s). | Q42021 |
Project Members | Organisation |
---|
Alan Shapiro | FDA |
Beilei Xu | Sanofi |
Carolyn Setze | AbbVie |
Cathy Bezek | Astellas |
Charles Beasley | MNS |
Elisa Young | Southern Star Research |
James Gaiser | Prometrika |
Joanne Zhou | GSK |
Jun Li | Sanofi |
Kim Musgrave | Amgen |
Project Members | Organisation |
Laura Goebel | Janssen Research & Development |
Melvin Munsaka | AbbVie |
Meredith Chuck | FDA |
Nancy Brucken | CSG |
Pranab Mitra | Industry |
Raj Phadtare | Corvus Pharma |
Ramaiah Muvvala | Inductive Quotient Analytics |
Robert (Mac) Gordon | Janssen Research & Development |
Russell Newhouse | Eli Lilly |
Simin K Baygani | Eli Lilly |
Tejas Patel | Booz Allen Hamilton |